Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab 1680 mg every 4 weeks in advanced solid tumors
jRCT2031220151Phase 2Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in Nonhematologic neoplasms, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Dose-limiting toxicity (DLT), Safety (adverse events) and 1 more. Started Sep 2022; status: completed.
02
Drugs
atezolizumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031220151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220151.